RADX

Positive safety and favourable biodistribution seen in all subjects dosed

Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company’s joint venture with MD Anderson Cancer Center Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in…

Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution SYDNEY, Aug.

RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 meeting with the U.S.

By John Vandermosten, CFA NASDAQ: RADX READ THE FULL RADX RESEARCH REPORT Fiscal 2026 Activity and Cash Flows Radiopharm Theranostics (NASDAQ: RADX) released its Quarterly Activities and Cash Report for its fourth quarter and fiscal year ending June 30 th , 2026.

Reported positive results from the Phase 2b clinical trial of imaging agent RAD 101, showing 93% of evaluable patients treated with RAD 101 achieved the primary endpoint Plans to initiate Phase 3 registrational trial of RAD 101 in Q4 2026 Raised approximately…

NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announces that it has entered into a Securities Purchase Agreement (“SPA”) with certain U.S.

First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed…

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective).